Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study
Falcone et al.
, Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective..
, Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa563
Prospective observational study of 315 hospitalized patients in Italy showing 65% lower mortality with HCQ. The median treatment delay was 6 days for survivors and 6.5 days for non-survivors. Mortality relative risk:
RR 0.35, p
= 0.2, propensity score matched
RR 0.75, p
= 0.36, multivariate Cox regression
RR 0.43, p
< 0.001, univariate Cox regression
risk of death, 65.0% lower, RR 0.35, p = 0.20, treatment 40 of 238 (16.8%), control 30 of 77 (39.0%), NNT 4.5, adjusted per study, PSM.
risk of death, 25.0% lower, RR 0.75, p = 0.36, treatment 40 of 238 (16.8%), control 30 of 77 (39.0%), NNT 4.5, adjusted per study, multivariate Cox regression.
risk of death, 57.0% lower, RR 0.43, p < 0.001, treatment 40 of 238 (16.8%), control 30 of 77 (39.0%), NNT 4.5, adjusted per study, univariate Cox regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Falcone et al., 19 Nov 2020, prospective, propensity score matching, Italy, peer-reviewed, 19 authors, average treatment delay 6.5 days.
Abstract: Open Forum Infectious Diseases
Role of Low-Molecular-Weight Heparin in
Hospitalized Patients With Severe Acute Respiratory
Syndrome Coronavirus 2 Pneumonia: A Prospective
Infectious Disease Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Emergency Medicine Unit, Department of Clinical and Experimental Medicine, University
Hospital of Pisa, Pisa, Italy, 3Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4Department of Surgical, Medical and Molecular Pathology and
Critical Care Medicine, University of Pisa, Pisa, Italy, 5Anaesthesia and Intensive Care Unit, Ospedali Galliera, Genova, Italy, 6Department of Anesthesia and Critical Care Medicine, Azienda
Ospedaliero Universitaria Pisana, Pisa, Italy, 7Department of Emergency Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, 8Geriatric Unit, Department of Clinical and Experimental
Medicine, University of Pisa, Pisa, Italy, 9Department of Internal Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, 10Virology Unit, Department of Laboratory Medicine Pisa University
Hospital and Retrovirus Center, Department of Translational Research, University of Pisa, Pisa, Italy, 11Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental
Medicine, University of Pisa, Pisa, Italy, 12Department of Economics and Finance University of Rome “Tor Vergata”, Rome, Italy
Background. This study was conducted to evaluate the impact of low-molecular-weight heparin (LMWH) on the outcome of
patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.
Methods. This is a prospective observational study including consecutive patients with laboratory-confirmed SARS-CoV-2
pneumonia admitted to the University Hospital of Pisa (March 4–April 30, 2020). Demographic, clinical, and outcome data were
collected. The primary endpoint was 30-day mortality. The secondary endpoint was a composite of death or severe acute respiratory distress syndrome (ARDS). Low-molecular-weight heparin, hydroxychloroquine, doxycycline, macrolides, antiretrovirals,
remdesivir, baricitinib, tocilizumab, and steroids were evaluated as treatment exposures of interest. First, a Cox regression analysis,
in which treatments were introduced as time-dependent variables, was performed to evaluate the association of exposures and outcomes. Then, a time-dependent propensity score (PS) was calculated and a PS matching was performed for each treatment variable.
Results. Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint
was achieved by 114 (36.2%) patients. Overall, 244 (77.5%) patients received LMWH, 238 (75.5%) received hydroxychloroquine,
201 (63.8%) received proteases inhibitors, 150 (47.6%) received doxycycline, 141 (44.8%) received steroids, 42 (13.3%) received
macrolides, 40 (12.7%) received baricitinib, 13 (4.1%) received tocilizumab, and 13 (4.1%) received remdesivir. At multivariate analysis, LMWH was associated with a reduced risk of 30-day mortality (hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.21–0.6;
P < .001) and composite endpoint (HR, 0.61; 95% CI, 0.39–0.95; P = .029). The PS-matched cohort of 55 couples confirmed the same
results for both primary and secondary endpoint.
Conclusions. This study suggests that LMWH might reduce the risk of in-hospital mortality and..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.